This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endologix Management Presents At Oppenheimer 22nd Annual Healthcare Conference - Conference Call Transcript

Endologix, Inc. ( ELGX)

Oppenheimer 22nd Annual Healthcare Conference

December 13, 2011, 09:40 a.m. ET


John McDermott - President and CEO


Steven Lichtman - Oppenheimer


Steven Lichtman - Oppenheimer

Welcome to the 22nd Annual Oppenheimer Healthcare Conference. We are going to kick it off this morning with a few medical device names. I’m very happy to have with us, first, John McDermott, Chief Executive Officer of Endologix, pure play in the abdominal aortic aneurysms market. We are going to a presentation here in the room and then we will open it up to some Q&A here in the room as well. So, with that I’m going to turn it over to John. Thanks sir.

John McDermott

Thanks Steve. Good morning everyone. Steve pointed out we are medical device company located in Irwin, California. We focus on repair of abdominal aortic aneurysms, I have got a several slides here. I’m going to take you through these pretty quickly just to make sure that we have plenty of time at the end for Q&A. It's a large and growing market, as I take you through the product portfolio you will see that we have got a very differentiated approach relative to our competitors treating aneurysms. The company has grown nicely or direct in the U.S. going direct right now in Europe. And as you can see from the sales figures here, plenty of resources continue the growth.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,025.82 -9.11 -0.05%
S&P 500 2,104.33 +3.93 0.19%
NASDAQ 5,017.5760 +22.9740 0.46%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs